Section III · Policy
Stat.
Policy analysis and descriptive statistics on regulatory approvals, clinical research authorization, and reimbursement trends in regenerative medicine.
Descriptive Statistical Report on Japan's Regenerative Medicine Clinical Practice and Product Development
Analysis of 6,770 provision plans as of March 31, 2026 — 98.8% treatment-purpose, Type III dominant, 16 new PMDA trial notifications
2026.03.31
Stat
Japan
regenerative medicine
regenerative medicine safety act
Statistical Report on Advanced Regenerative Medicine Clinical Research Authorization in South Korea
Analysis of 60 cases as of March 2026 — cell therapy dominant, oncology leads, concentrated in major tertiary hospitals
2026.03.31
Stat
첨단재생의료
임상연구
세포치료